Home › Companies › Filana Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Filana Therapeutics, Inc.’s Form 8-K, filed June 15, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 11, 2026: 6 items on Filana Therapeutics, Inc.’s Form 8-K, filed June 15, 2026: 3 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Filana Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Filana Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 15, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard J. Barry | 8,851,285 | -- | -- | 1,564,191 | 14,144,300 | 85% | Not verified | — |
| Elect Director: Pierre Gravier | 9,069,595 | -- | -- | 1,345,881 | 14,144,300 | 87% | Not verified | — |
| Elect Director: Claude Nicaise, M.D. | 8,924,355 | -- | -- | 1,491,121 | 14,144,300 | 86% | Not verified | — |
| 2. An amendment to the Company's 2018 Omnibus Incentive Plan | 8,427,565 | 1,869,290 | 118,621 | -- | 14,144,300 | 82% | Approved | — |
| 3. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 | 22,671,610 | 1,408,513 | 479,653 | -- | -- | 94% | Approved | — |
| 4. 2025 executive compensation for the Company's named executive officers | 7,487,142 | 2,827,840 | 100,494 | -- | 14,144,300 | 73% | Approved | — |
Source: Filana Therapeutics, Inc., Form 8-K, filed with the SEC on June 15, 2026 — read the filing on EDGAR.
Each item below shows how the 105 asset managers that disclosed a Filana Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Claude Nicaise, M.D.
Filana Therapeutics, Inc.’s own tally for this item (“Elect Director: Claude Nicaise, M.D.”): 8,924,355 for, 1,491,121 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 2,710,290 for, 31,929 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,992,398 | 0 | 7 | 0 | For |
| Fidelity | 501,287 | 0 | 0 | 0 | For |
| Dimensional | 81,961 | 0 | 0 | 0 | For |
| BlackRock | 62,003 | 0 | 0 | 0 | For |
| Goldman Sachs | 28,701 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 25,000 | Withhold |
| American Century | 13,408 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,600 | 0 | 0 | 0 | For |
| Invesco | 7,230 | 0 | 0 | 0 | For |
| Equitable | 7,177 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 6,697 | Withhold |
| Victory Capital | 4,877 | 0 | 0 | 0 | For |
| Guggenheim | 448 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 232 | Withhold |
| MARCO INVESTMENT MANAGEMENT LLC | 200 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Pierre Gravier
Filana Therapeutics, Inc.’s own tally for this item (“Elect Director: Pierre Gravier”): 9,069,595 for, 1,345,881 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 2,742,220 for, 6 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,992,399 | 0 | 6 | 0 | For |
| Fidelity | 501,287 | 0 | 0 | 0 | For |
| Dimensional | 81,961 | 0 | 0 | 0 | For |
| BlackRock | 62,003 | 0 | 0 | 0 | For |
| Goldman Sachs | 28,701 | 0 | 0 | 0 | For |
| Charles Schwab | 25,000 | 0 | 0 | 0 | For |
| American Century | 13,408 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,600 | 0 | 0 | 0 | For |
| Invesco | 7,230 | 0 | 0 | 0 | For |
| Equitable | 7,177 | 0 | 0 | 0 | For |
| Northern Trust | 6,697 | 0 | 0 | 0 | For |
| Victory Capital | 4,877 | 0 | 0 | 0 | For |
| Guggenheim | 448 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 232 | 0 | 0 | 0 | For |
| MARCO INVESTMENT MANAGEMENT LLC | 200 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Richard J. Barry
Filana Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard J. Barry”): 8,851,285 for, 1,564,191 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 2,737,359 for, 4,858 withheld, 9 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,987,770 | 0 | 9 | 4,626 | For |
| Fidelity | 501,287 | 0 | 0 | 0 | For |
| Dimensional | 81,961 | 0 | 0 | 0 | For |
| BlackRock | 62,003 | 0 | 0 | 0 | For |
| Goldman Sachs | 28,701 | 0 | 0 | 0 | For |
| Charles Schwab | 25,000 | 0 | 0 | 0 | For |
| American Century | 13,408 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,600 | 0 | 0 | 0 | For |
| Invesco | 7,230 | 0 | 0 | 0 | For |
| Equitable | 7,177 | 0 | 0 | 0 | For |
| Northern Trust | 6,697 | 0 | 0 | 0 | For |
| Victory Capital | 4,877 | 0 | 0 | 0 | For |
| Guggenheim | 448 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 232 | Withhold |
| MARCO INVESTMENT MANAGEMENT LLC | 200 | 0 | 0 | 0 | For |
82% Approved · of votes cast
Description as filed by funds: TO APPROVE AMENDMENT NO. 2 TO THE COMPANY'S 2018 OMNIBUS INCENTIVE PLAN, WHICH, AMONG OTHER THINGS, INCREASES THE AUTHORIZED NUMBER OF SHARES ISSUABLE THEREUNDER BY 4,000,000 SHARES (FROM 5,000,000 TO 9,000,000 AUTHORIZED SHARES).
Filana Therapeutics, Inc.’s own tally for this item (“2. An amendment to the Company's 2018 Omnibus Incentive Plan”): 8,427,565 for, 1,869,290 against — passed, per its Form 8-K filed June 15, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two – An amendment to the Company's 2018 Omnibus Incentive Plan was approved based upon the following votes:”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 2,696,546 for, 46,980 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,987,766 | 4,639 | 1 | 0 | For |
| Fidelity | 501,287 | 0 | 0 | 0 | For |
| Dimensional | 81,961 | 0 | 0 | 0 | For |
| BlackRock | 62,003 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 28,701 | 0 | 0 | Against |
| Charles Schwab | 25,000 | 0 | 0 | 0 | For |
| American Century | 0 | 13,408 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 10,600 | 0 | 0 | 0 | For |
| Invesco | 7,230 | 0 | 0 | 0 | For |
| Equitable | 7,177 | 0 | 0 | 0 | For |
| Northern Trust | 6,697 | 0 | 0 | 0 | For |
| Victory Capital | 4,877 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 1,500 | 0 | 0 | 0 | For |
| Guggenheim | 448 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 232 | 0 | 0 | Against |
Combines 5 wordings of this item as funds reported it.
73% Approved · of votes cast
Description as filed by funds: TO APPROVE, BY A NON-BINDING ADVISORY VOTE, 2025 EXECUTIVE COMPENSATION FOR THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Filana Therapeutics, Inc.’s own tally for this item (“4. 2025 executive compensation for the Company's named executive officers”): 7,487,142 for, 2,827,840 against — passed, per its Form 8-K filed June 15, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Four – The 2025 executive compensation for the Company's named executive officers was approved, on a non-binding advisory vote, based upon the following votes:”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,990,099 | 2,304 | 1 | 0 | For |
| Fidelity | 501,287 | 0 | 0 | 0 | For |
| Dimensional | 0 | 81,961 | 0 | 0 | Against |
| BlackRock | 62,003 | 0 | 0 | 0 | For |
| Goldman Sachs | 28,701 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 25,000 | 0 | 0 | Against |
| American Century | 13,408 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,600 | 0 | 0 | 0 | For |
| Invesco | 0 | 7,230 | 0 | 0 | Against |
| Equitable | 7,177 | 0 | 0 | 0 | For |
| Northern Trust | 6,697 | 0 | 0 | 0 | For |
| Victory Capital | 4,877 | 0 | 0 | 0 | For |
| Guggenheim | 448 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 232 | 0 | 0 | 0 | For |
| FORUM FUNDS | 50 | 0 | 0 | 0 | For |
Fund voting reports, all 15 managers: 2,625,579 for, 116,495 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 714,985 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 608,564 | 0 | 0 | 0 | For |
| Two Sigma | 472,312 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 376,656 | 0 | 0 | Against |
| GMT CAPITAL CORP | 0 | 375,346 | 0 | 0 | Against |
| Vanguard | 304,819 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 206,150 | 0 | 0 | 0 | For |
| CANADA PENSION PLAN INVESTMENT BOARD | 189,100 | 0 | 0 | 0 | For |
| DE Shaw | 102,136 | 0 | 0 | 0 | For |
| T. Rowe Price | 94,104 | 0 | 0 | 0 | For |
| Federated Hermes | 81,746 | 0 | 0 | 0 | For |
| Northern Trust | 78,218 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 70,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 66,007 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 40,754 | 0 | 0 | 0 | For |
| Cerity Partners LLC | 0 | 35,000 | 0 | 0 | Against |
| Charles Schwab | 0 | 25,000 | 0 | 0 | Against |
| Dimensional | 0 | 23,953 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 22,591 | 0 | 0 | Against |
| State Street | 21,457 | 0 | 0 | 0 | For |
| American Century | 13,408 | 0 | 0 | 0 | For |
| JOHNSON INVESTMENT COUNSEL INC | 12,000 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 10,651 | 0 | 0 | 0 | For |
| MML INVESTORS SERVICES, LLC | 9,450 | 0 | 0 | 0 | For |
| Invesco | 0 | 7,230 | 0 | 0 | Against |
Institutional-manager reports, all 99 managers: 3,158,344 for, 883,318 against, 200 abstained, 1,510 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR FISCAL YEAR ENDING DECEMBER 31, 2026.
Filana Therapeutics, Inc.’s own tally for this item (“3. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026”): 22,671,610 for, 1,408,513 against — passed, per its Form 8-K filed June 15, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026, was ratified based upon the following votes:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 2,739,711 for, 2,514 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,990,122 | 2,282 | 1 | 0 | For |
| Fidelity | 501,287 | 0 | 0 | 0 | For |
| Dimensional | 81,961 | 0 | 0 | 0 | For |
| BlackRock | 62,003 | 0 | 0 | 0 | For |
| Goldman Sachs | 28,701 | 0 | 0 | 0 | For |
| Charles Schwab | 25,000 | 0 | 0 | 0 | For |
| American Century | 13,408 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 10,600 | 0 | 0 | 0 | For |
| Invesco | 7,230 | 0 | 0 | 0 | For |
| Equitable | 7,177 | 0 | 0 | 0 | For |
| Northern Trust | 6,697 | 0 | 0 | 0 | For |
| Victory Capital | 4,877 | 0 | 0 | 0 | For |
| Guggenheim | 448 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 232 | 0 | 0 | Against |
| MARCO INVESTMENT MANAGEMENT LLC | 200 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 48,297,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.13% |
| 2 | Fidelity | 1.04% |
| 3 | Dimensional | 0.17% |
| 4 | BlackRock | 0.13% |
| 5 | Goldman Sachs | 0.06% |
| 6 | Charles Schwab | 0.05% |
| 7 | American Century | 0.03% |
| 8 | Blackstone Alternative Investment Funds | 0.02% |
| 9 | Invesco | 0.01% |
| 10 | Equitable | 0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 1.48% |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 1.26% |
| 3 | Two Sigma | 0.98% |
| 4 | MARSHALL WACE, LLP | 0.78% |
| 5 | GMT CAPITAL CORP | 0.78% |
| 6 | Vanguard | 0.63% |
| 7 | ACADIAN ASSET MANAGEMENT LLC | 0.43% |
| 8 | CANADA PENSION PLAN INVESTMENT BOARD | 0.39% |
| 9 | DE Shaw | 0.21% |
| 10 | T. Rowe Price | 0.19% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 4.92% | 13F |
| Two Sigma | 4.12% | 13F |
| BlackRock | 2.93% | 13F |
| Richard J. Barry | 2.52% | DEF14A |
| Geode Capital | 1.23% | 13F |
| D.E. Shaw | 1.16% | 13F |
| Renaissance Technologies | 0.68% | 13F |
| Citadel Advisors | 0.64% | 13F |
| State Street | 0.50% | 13F |
| Dimensional Fund Advisors | 0.50% | 13F |
Percentages above are of 48,297,000 shares outstanding, as reported by Filana Therapeutics, Inc. on its Form 10-K dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Filana Therapeutics, Inc.’s 10-K dated December 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Filana Therapeutics, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 105 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 357 separate fund positions. On the most widely held item on that ballot — TO APPROVE, BY A NON-BINDING ADVISORY VOTE, 2025 EXECUTIVE COMPENSATION FOR THE COMPANY'S NAMED… — Filana Therapeutics, Inc.'s filing reports the proposal as approved, with 73% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Filana Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 15, 2026.
Filana Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.